Halozyme Therapeutics, Inc. (HALO), a biopharmaceutical company, Wednesday said that it has raised both its fiscal 2025 revenue guidance and its fiscal 2026 outlook.
Now, the company expects total revenue in the range of $1.385 billion to $1.4 billion with a surmised growth of 36 percent to 38 percent.
Previously, it expected total revenue in the range of $1.3 billion to $1.375 billion.For the full year 2026, the current total revenue is expected to be between $1,710 million and $1,810 million with a growth rate of 23 percent to 30 percent compared to the previous range of $1,430 to $1,530 million.
Presently, Adjusted EPS is expected to be between $7.75 and $8.25 compared to the prior range of $6.50 to $7.
In pre-market activity, HALO shares were trading at $70.35, up 0.19% on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.